Acne vulgaris - Pipeline Insight, 2022

DelveInsight’s, “Acne vulgaris - Pipeline Insight, 2022,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Acne vulgaris Understanding
Acne vulgaris: Overview
Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, which runs a chronic course and it is self-limiting. Acne vulgaris is triggered by Cutibacterium acnes in adolescence, under the influence of normal circulating dehydroepiandrosterone (DHEA). It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne may appear in adolescence, and it persists through the early thirties. Acne is more common in males than in females. Urban populations are more affected than rural populations. About 20% of the affected individuals develop severe acne, which results in scarring. Some races appear to be more affected than others. Acne occurs by hypersensitivity of the sebaceous glands to a normal circulating level of androgens, which are aggravated by P. acnes and inflammation. Acne vulgaris is diagnosed clinically. However, in women of childbearing age, one should ask for a history of hirsutism or dysmenorrhea. If positive, then levels of testosterone, LH, FSH, and DHEA should be ordered. Topical retinoids like retinoic acid, adapalene, and tretinoin are used alone or with other topical antibiotics or benzoyl peroxide. Retinoic acid is the best comedolytic agent, available as 0.025%, 0.05%, 0.1% cream, and gel. Azelaic acid is antimicrobial and comedolytic available 15% or 20% gel. It can also be used in postinflammatory pigmentation of acne. An oral contraceptive containing low dose estrogen 20 mcg along with cyproterone acetate as anti-androgens are used for severe recurrent acne.

Acne vulgaris Emerging Drugs Chapters
This segment of the Acne vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acne vulgaris Emerging Drugs
IDP126: Bausch Health Americas, Inc.
A fixed dose combination of adapalene, benzoyl peroxide and clindamycin phosphate gel formulation, designated as IDP 126, is being developed by Bausch. In June 2021, Ortho Dermatologics, a Bausch Health Company, announced results from its second phase III trial investigating the safety and efficacy of IDP-126 (Ortho Dermatologics)) for the treatment of acne vulgaris in patients 9 years and older. This study, a phase III, multicenter, randomized, double-blind, vehicle-controlled trial, met all coprimary endpoints by week 12. The endpoints were the absolute change from baseline in inflammatory lesion count and noninflammatory lesion count, and percentage of patients who achieved treatment success. The treatment success was defined as clear or almost clear skin in the Evaluator’s Global Severity Score (EGSS).
DMT310: Dermata Therapeutics
DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties.Currently it is being evaluated in Phase II stage of development to treat acne vulgaris.
Further product details are provided in the report……..

Acne vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Acne vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Acne vulgaris
There are approx. 22+ key companies which are developing the therapies for Acne vulgaris. The companies which have their Acne vulgaris drug candidates in the mid to advanced stage, i.e. Phase III include, Bausch Health Americas, Inc.
Phases
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Late-stage products (Phase III )
Mid-Stage products (Phase II)
Early-stage products ( Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Acne vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Oral
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Peptide
Antibiotics
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acne vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acne vulgaris therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acne vulgaris drugs.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Acne vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Acne vulgaris.

Acne vulgaris Report Insights
Acne vulgaris Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs
Acne vulgaris Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Acne vulgaris drugs?
How many Acne vulgaris drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acne vulgaris?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acne vulgaris therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Acne vulgaris and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Novan, Inc.
Bausch Health Americas, Inc.
AOBiome LLC
Ascletis Pharmaceuticals
AnaptysBio, Inc.
Botanix Pharmaceuticals
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Xenon Pharmaceuticals Inc.
Origimm Biotechnology
Boston Pharmaceuticals
Kintor Pharma
Dermavant Sciences
Eligo Bioscience
Cassiopea, Inc.
BioPharmX
Madam Therapeutics
SiSaf

Key Products
SB204
IDP-126
B244
ASC40
Imsidolimab
BTX 1503
UHE-101
XPF-005
ORG101
BOS-356
BPX-01
Aminolevulinic acid (ALA)

Companies

Novan, Inc.
Bausch Health Americas, Inc.
AOBiome LLC
Ascletis Pharmaceuticals
AnaptysBio, Inc.
Botanix Pharmaceuticals
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Xenon Pharmaceuticals Inc.
Origimm Biotechnology
Boston Pharmaceuticals
Kintor Pharma
Dermavant Sciences
Eligo Bioscience
Cassiopea, Inc.
BioPharmX
Madam Therapeutics
SiSaf